IsoPlexis Partnering With Yale on Assays for Assessing Immune Response to COVID-19

IsoPlexis Partnering With Yale on Assays for Assessing Immune Response to COVID-19

Single-cell proteomics firm IsoPlexis said Thursday that it is partnering with Yale University to develop assays for COVID-19 using the company’s IsoLight system. According to the company, the partners aim to identify markers of patient immune response to the virus that could be used to inform development of therapies and vaccines for the disease.